IFRX's logo.
Ticker Symbol: IFRX

InflaRx N.V.

$4.86 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: Germany Currency: USD Asset Type: Common Stock CIK:0001708688

Company Profile

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: Winzerlaer Str. 2
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $2.61
Change: -$0.01 ( -0.57%)
Days Range: $2.50 - $2.80
Beta: 0.38
52wk. High: $7.25
52wk. Low: $1.57
Ytd. Change -15.89%
50 Day Moving Average: $3.09
200 Day Moving Average: $3.98
Shares Outstanding: 44703763

Valuation

Market Cap: 11.7B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A